All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Alexion's Koselugo selumetinib wins EU approval for neurofibromatosis type 1 plexiform neurofibromas in adults
Small molecule, rare disease, MEK inhibitor, neurofibromatosis type 1, plexiform neurofibromas - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly, Nvidia partner to build pharma's “most powerful” supercomputer for drug discovery
Technology collaboration, AI/ML, drug discovery, manufacturing - Read more

Onward Therapeutics exercises option, licenses Institut du Cancer de Montpellier's onco-metabolism program OT-S00X
Licensing deal, oncology, onco-metabolism, small molecule, AI/ML - Read more

Swarm Oncology, leading US clinic collaborate on T cell therapies for advanced solid cancers
Research collaboration, oncology, cell therapy, manufacturing - Read more

Mark Cuba’s Cost Plus Drugs, MedChat AI partner on AI agents for online pharmacy customer support
Technology partnership, AI/ML, digital health, customer support - Read more

PRESENTED BY SCILEADS
Find & Engage High-Intent Biotech, Pharma, and Academic Prospects with SciLeads

SciLeads is the all-in-one solution for scientific lead generation.

🤩Use tradeshow, funding, and publication intelligence to find leads and create engaging messages that convert them to customers.

👉 Start your free trial today by clicking here!

✅ More Good News ✅

THE GOOD
Clinical Trials

Merck & Co.'s Welireg belzutifan plus Keytruda shows Ph3 success in clear cell renal cell carcinoma adjuvant treatment
Small molecule, cancer, HIF-2α inhibitor, renal cell carcinoma, combination therapy - Read more

Jupiter Endovascular's Vertex TFX catheter platform shows positive Ph1 results for acute pulmonary embolism treatment
Medical device, cardiovascular, catheter system, pulmonary embolism, endovascular therapy - Read more

Edesa's paridiprubart anti-TLR4 antibody shows Ph3 survival benefit for acute respiratory distress syndrome patients
Antibody, infectious disease, monoclonal antibody, COVID-19, TLR4 target, ARDS - Read more

Biogen's dapirolizumab pegol shows quality of life benefits in Ph3 systemic lupus erythematosus study
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, CD40L inhibitor, quality of life - Read more

Bristol Myers Squibb and Cabaletta Bio's resecabtagene autoleucel CAR-T shows remissions in Ph1/2 systemic lupus erythematosus trial
Cell therapy, autoimmune, CAR-T, systemic lupus erythematosus, lupus nephritis, CD19 target - Read more

Lumosa Therapeutics reports positive Ph2b results for Odatroltide in acute ischemic stroke patients
Protein therapy, neurological, acute ischemic stroke, neuroprotection, large artery atherosclerosis - Read more

Sudo Biosciences reports positive Ph1 results for SUDO-550 tyrosine kinase 2 inhibitor targeting neuroinflammatory diseases
Small molecule, neurological, TYK2 inhibitor, multiple sclerosis, neuroinflammation, CNS-penetrant - Read more

THE GOOD
Company Launches

Zag Bio debuts with $80M Series A to develop thymus-targeted autoimmune therapies
Bifunctional antibody, autoimmune, strategic, major transaction - Read more

THE GOOD
Earnings & Finances

Novartis Q3 revenue rises 8% to $13.9B as new drugs offset Entresto generic competition
Small molecule, cardiovascular, financial, generic competition, revenue impact - Read more

THE GOOD
Fundraises

Cellcolabs raises $12M primary funding, industrial-scale mesenchymal stem cell production
Cell therapy, manufacturing, mesenchymal stem cells, GMP production - Read more

GHO Capital raises $2.9B fourth PE fund, European healthcare specialist investments
Healthcare investment, private equity, multi-sector healthcare - Read more

Cybin raises $175M registered direct offering, Phase 3 neuropsychiatry mental healthcare company
Neuropsychiatry, clinical-stage, drug discovery, platform technology - Read more

X4 Pharmaceuticals raises $155M public offering, rare hematology diseases treatments
Rare disease, hematology, small molecule, clinical-stage - Read more

Context Therapeutics expands ATM offering to $75M for R&D and acquisitions
Oncology, clinical-stage - Read more

THE GOOD
Product Launches

Invert launches first-to-market AI chat interface for biomanufacturing process optimization and development
Cell and gene therapy, bioprocessing, operational, cost reduction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects Regeneron's Eylea HD prefilled syringe application again due to manufacturing partner facility issues
Protein therapy, ophthalmology, VEGF inhibitor, macular degeneration, retinal vein occlusion, manufacturing issues - Read more

THE BAD
Clinical Trials

Incyte discontinues INCB57643 BET inhibitor Ph2 development for myelofibrosis amid class safety concerns
Small molecule, cancer, BET inhibitor, myelofibrosis, safety concerns - Read more

THE BAD
Lawsuits

Texas Attorney General sues Kenvue over alleged deceptive Tylenol marketing linked to autism risk
Small molecule, neurological, regulatory, operational - Read more

THE BAD
Politics & Policy

Novartis CEO says Trump drug pricing deals don't address root causes during Q3 earnings call
Pharmaceuticals, strategic, regulatory, financial - Read more

THE BAD
Regulatory

UK extends deadline for pharma companies to exit 23% medicine rebate scheme amid pricing tensions
Regulatory, financial, strategic, operational - Read more

THE BAD
Strategic Plans

Aldeyra stops ADX-629 development, swaps priority molecules in metabolic inflammation and dry AMD programs
Small molecule, metabolic, strategic, operational - Read more

CSL delays flu vaccine unit spinoff as US immunization rates drop 12%
Vaccine, infectious disease, strategic, financial - Read more

BioMarin abandons Roctavian gene therapy, cuts revenue guidance amid Voxzogo competitive threats from Ascendis, BridgeBio
Gene therapy, rare disease, strategic, revenue impact, competitive - Read more

Akebia abandons Vafseo vadadustat label expansion for chronic kidney disease patients not on dialysis
Small molecule, chronic kidney disease, HIF-PH inhibitor, anemia, dialysis patients - Read more

THE UGLY
Regulatory

FDA blasts Hetero Labs with Form 483 citing birds, lizards, cats in contaminated Indian warehouse
Generic drugs, regulatory, operational, manufacturing quality - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here